NEOS Investment Management LLC Lowers Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

NEOS Investment Management LLC cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 51.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,563 shares of the biopharmaceutical company’s stock after selling 2,738 shares during the quarter. NEOS Investment Management LLC’s holdings in Alnylam Pharmaceuticals were worth $1,169,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. OFI Invest Asset Management boosted its position in shares of Alnylam Pharmaceuticals by 5.8% in the third quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 22 shares during the period. Howard Capital Management Inc. lifted its holdings in shares of Alnylam Pharmaceuticals by 2.9% during the third quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company’s stock valued at $389,000 after purchasing an additional 24 shares during the last quarter. Frank Rimerman Advisors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 2.0% in the third quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company’s stock worth $570,000 after buying an additional 24 shares during the period. Coastal Bridge Advisors LLC grew its position in Alnylam Pharmaceuticals by 2.3% during the 3rd quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company’s stock worth $500,000 after purchasing an additional 25 shares in the last quarter. Finally, Meridian Financial Advisors LLC raised its position in Alnylam Pharmaceuticals by 3.5% during the third quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company’s stock valued at $378,000 after buying an additional 28 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Activity

In related news, EVP Kevin Joseph Fitzgerald sold 2,041 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $331.96, for a total value of $677,530.36. Following the completion of the sale, the executive vice president owned 21,264 shares in the company, valued at approximately $7,058,797.44. This represents a 8.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Jeffrey V. Poulton sold 2,242 shares of the stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $695,199.36. Following the completion of the sale, the executive vice president owned 59,802 shares in the company, valued at $18,543,404.16. This represents a 3.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 36,578 shares of company stock worth $12,416,105. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $336.19 on Friday. The stock has a 50-day simple moving average of $366.89 and a 200 day simple moving average of $422.44. The stock has a market capitalization of $44.59 billion, a price-to-earnings ratio of 196.60 and a beta of 0.35. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.61). The company had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company’s revenue was up 84.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.65) EPS. On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Company reported ~ $3.0B in 2025 revenue (≈81% YoY) with Q4 net product revenue of $995M and a 151% surge in the TTR franchise — evidence of accelerating commercial momentum that supports longer‑term growth expectations. Alnylam Pharmaceuticals (ALNY) Reports $3B 2025 Revenue Driven by 151% TTR Franchise Surge
• Positive Sentiment: Canaccord Genuity raised its price target to $429, signaling stronger upside in analysts’ models and providing support for the stock’s valuation case. Canaccord Genuity Group Increases Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $429.00
• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating, and Freedom Capital upgraded ALNY to “Strong Buy” (reported via Zacks), adding buy‑side endorsement that could attract momentum investors. HC Wainwright Reaffirms “Buy” Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) Freedom Capital Upgrade via Zacks
• Neutral Sentiment: Some analysts trimmed targets after the latest reports while still expressing confidence in 2026 growth — a mixed read that leaves upside intact but tempers near‑term estimates. Analysts Trim Alnylam Pharmaceuticals, Inc. (ALNY) Targets but Keep Faith in 2026 Growth
• Neutral Sentiment: Independent valuation pieces highlight a divergence between recent share‑price performance and bullish fair‑value models — useful context for investors debating entry points. Assessing Alnylam Pharmaceuticals (ALNY) Valuation As Mixed Share Price Returns Meet Bullish Fair Value Models
• Negative Sentiment: Insider selling picked up this week: an EVP sold ~$607,447 of stock, and two other officers (Kevin Joseph Fitzgerald and Pushkal Garg) sold shares (2,041 and 2,242 shares respectively). Insider sales can create short‑term sentiment pressure even if they are routine. Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $607,446.72 in Stock Kevin Joseph Fitzgerald Sells 2,041 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Pushkal Garg Sells 2,242 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Piper Sandler reiterated an “overweight” rating and set a $489.00 price objective (up from $449.00) on shares of Alnylam Pharmaceuticals in a report on Friday, October 31st. Raymond James Financial reaffirmed an “outperform” rating and set a $472.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, January 12th. Leerink Partners lowered their price objective on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a research report on Monday, December 15th. Royal Bank Of Canada cut their price target on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating for the company in a research note on Tuesday, January 20th. Finally, HC Wainwright reissued a “buy” rating and set a $510.00 price target on shares of Alnylam Pharmaceuticals in a report on Wednesday. One analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $477.96.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.